Compare GREE & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GREE | DARE |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | 32 | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.3M | 21.6M |
| IPO Year | N/A | 2014 |
| Metric | GREE | DARE |
|---|---|---|
| Price | $1.30 | $2.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 177.3K | ★ 845.0K |
| Earning Date | 05-15-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,807,885.00 |
| Revenue This Year | N/A | $2,115.12 |
| Revenue Next Year | N/A | $122.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.00 | $1.27 |
| 52 Week High | $2.42 | $9.19 |
| Indicator | GREE | DARE |
|---|---|---|
| Relative Strength Index (RSI) | 51.83 | 45.31 |
| Support Level | $1.09 | $1.79 |
| Resistance Level | $1.39 | $2.54 |
| Average True Range (ATR) | 0.12 | 0.39 |
| MACD | 0.02 | -0.10 |
| Stochastic Oscillator | 42.46 | 13.05 |
Greenidge Generation Holdings Inc owns and operates a vertically integrated cryptocurrency data center. The company has one reportable segment: The Datacenter Operations segment, that derives revenue through datacenter hosting, crypto-currency self-mining, and power and capacity sales. It owns and operate a vertically integrated cryptocurrency datacenter and power generation facility in Torrey, New York, which includes a natural gas power generation plant of nameplate capacity. The cryptocurrency data center operations generate revenue in the form of bitcoin by earning bitcoin as rewards and transaction fees for supporting the bitcoin network with application-specific integrated circuit computers owned or leased by the company.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.